RxDoctor Payments DataLook up a doctor →

Asim Chohan, MD

Cardiovascular Disease · Midwest City, OKNPI 1386793156

Payments from drug & device makers

$19,179in general payments, 2019–2025

Across 732 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • AstraZeneca$1K
  • Amgen$1K
  • Edwards Lifesciences$1K
  • Pfizer$1K
  • Medtronic$1K
  • plus $10K from 39 others

What the payments were for

  • Travel & lodging$3,52218%
  • Food & beverage$15,57681%
  • Education$810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,179 in reported general payments places this provider in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$849,411
Medicare patients
1,639
Services billed
7,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban579$581,568
VyndamaxTafamidis12$280,500
EntrestoSacubitril/Valsartan118$126,428
XareltoRivaroxaban103$107,073
JardianceEmpagliflozin76$64,550
FarxigaDapagliflozin Propanediol40$34,286
Repatha SureclickEvolocumab37$34,281
VerquvoVericiguat20$18,316
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,444
CorlanorIvabradine Hcl17$15,843
BrilintaTicagrelor22$11,486
Clonidine52$9,670
ClopidogrelClopidogrel Bisulfate523$9,536
Rosuvastatin Calcium533$8,377
Atorvastatin Calcium440$7,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$1,176$862,068591 claims
NovartisEntresto$852$126,428118 claims
Johnson & JohnsonXarelto$1,018$107,073103 claims
Boehringer IngelheimJardiance$768$64,55076 claims
AstraZenecaFarxiga, Brilinta$1,301$45,77262 claims
MerckVerquvo$642$18,31620 claims
GSKTrelegy Ellipta$52$16,44424 claims
AmgenCorlanor$1,268$15,84317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Midwest City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →